<DOC>
	<DOCNO>NCT01348139</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics pharmacodynamics single dos three different dry powder inhalation formulation AZD3199 administer via Single Inhalation Device ( SID ) compare AZD3199 administer via Turbuhaler™ Inhaler compare placebo patient persistent asthma .</brief_summary>
	<brief_title>Evaluation Pharmacokinetics Pharmacodynamics Different Dry Powder Inhalation Formulations AZD3199 Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>AZD-3199</mesh_term>
	<criteria>Provision sign date write informed consent prior study specific procedure Men woman , age ≥ 18 year . Women must nonchildbearing potential stable highly effective contraceptive method least 3 month prior Visit 1 willing continue choose contraceptive method throughout study . Be nonsmoker exsmoker stop smoke &gt; 6 month prior study start A history asthma least 6 month . Body Mass Index ( BMI ) 1930 kg/m2 Significant disease disorder , opinion Investigator , may either put patient risk participation study , influence result study , patient 's ability participate study History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge Investigator history hypersensitivity β2agonists general AZD3199 and/or excipients Prolonged QTcF &gt; 450 msec shorten QTcF &lt; 340 msec History alcohol/drug abuse excessive intake alcohol judge Investigator Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>patient</keyword>
	<keyword>lung function</keyword>
</DOC>